A Longitudinal Comparison of the Recovery Patterns of Optic Neuritis with MOG Antibody-Seropositive and AQP4 Antibody-Seropositive or -Seronegative for Both Antibodies
- PMID: 35360549
- PMCID: PMC8964224
- DOI: 10.1155/2022/4951491
A Longitudinal Comparison of the Recovery Patterns of Optic Neuritis with MOG Antibody-Seropositive and AQP4 Antibody-Seropositive or -Seronegative for Both Antibodies
Abstract
In this study, the aim is to compare the recovery pattern among patients with acute myelin oligodendrocyte glycoprotein antibody-seropositive optic neuritis (MOG-Ab + ON) attacks and aquaporin-4 antibody-seropositive ON (AQP4-Ab + ON) or -seronegative ON. At the onset of the first-ever ON attack, the thickness of RNFL (RNFLt) in the MOG-Ab + ON group was significantly thicker than others (P < 0.05), while visual function damage was not significantly different to other groups. One month to six months after onset, the MOG-Ab + ON group showed significantly better visual function (P < 0.05) than the other two groups, while the RNFLt showed no significant difference among the three groups (P > 0.05). MOG-Ab + ON and AQP4-Ab + ON groups showed rapid recovery in the first month and then plateaued. The annual relapse rate was significantly higher in MOG-Ab + ON and AQP4-Ab + ON groups than seronegative ON. The relapse interval of the MOG-Ab + ON group (9.00 ± 7.86 months) was significantly shorter than that of the AQP4-Ab + ON group (45.76 ± 37.82 months) (P < 0.05) but showed no significant difference from that of the seronegative ON group (P > 0.05). To sum up, the recovery patterns were different among these three types of ON. RNFLt was not parallel to the recovery of visual function among these types of ON. MOG-Ab + ON had the mildest visual function damage but the most substantial RNFL changes, while AQP4-Ab + ON suffered the worst function damage. MOG-Ab + ON had a similar relapse rate as AQP4-Ab + ON but a shorter interval, indicating that relapse prevention was necessary and should be initiated as early as possible.
Copyright © 2022 Lin Zhou et al.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures





Similar articles
-
Clinical characteristics and prognosis of myelin oligodendrocyte glycoprotein antibody-seropositive paediatric optic neuritis in China.Br J Ophthalmol. 2019 Jun;103(6):831-836. doi: 10.1136/bjophthalmol-2018-312399. Epub 2018 Jul 26. Br J Ophthalmol. 2019. PMID: 30049802
-
Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China.J Neurol. 2018 Jan;265(1):33-40. doi: 10.1007/s00415-017-8651-4. Epub 2017 Nov 3. J Neurol. 2018. PMID: 29101456
-
Clinical Profile of Anti-Myelin Oligodendrocyte Glycoprotein Antibody Seropositive Cases of Optic Neuritis.Neuroophthalmology. 2015 Aug 25;39(5):213-219. doi: 10.3109/01658107.2015.1072726. eCollection 2015 Oct. Neuroophthalmology. 2015. PMID: 27928358 Free PMC article.
-
Current understanding of the epidemiologic and clinical characteristics of optic neuritis.Jpn J Ophthalmol. 2021 Jul;65(4):439-447. doi: 10.1007/s10384-021-00840-w. Epub 2021 May 22. Jpn J Ophthalmol. 2021. PMID: 34021411 Review.
-
Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide.Front Neurol. 2020 Jun 26;11:501. doi: 10.3389/fneur.2020.00501. eCollection 2020. Front Neurol. 2020. PMID: 32670177 Free PMC article. Review.
Cited by
-
Visual improvement in a case of neuromyelitis optica spectrum disorder-related optic neuritis after 18 months of treatment with satralizumab: A case report.Heliyon. 2024 Jul 25;10(15):e35142. doi: 10.1016/j.heliyon.2024.e35142. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39157378 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Miscellaneous